• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr David Kingdon Describes Reactions to Increasing Use of CBT for Psychosis

Video

David Kingdon, MD, professor of mental health care delivery, University of Southampton, explained that mental health professionals have been receptive to the use of cognitive behavioral therapy (CBT) in psychosis, but there needs to be greater expansion to increase availability.

David Kingdon, MD, professor of mental health care delivery, University of Southampton, explained that mental health professionals have been receptive to the use of cognitive behavioral therapy (CBT) in psychosis, but there needs to be greater expansion to increase availability.

Transcript

In your experience, have mental health care providers and patients been receptive to the increasing use of CBT in psychosis?

I think when we’ve met people and talked with them and when they’ve understood what’s involved, they have been very receptive, because it is something that patients value very, very much, and carers value, so we did a number of sessions at the National Alliance for the Mentally Ill last year, which went down really well; we had a great time there, lot of sharing of experience and understanding. But in terms of service providers, in the UK particularly it’s become quite widespread, but it’s also happening in the US as well, and I think CBT techniques are used partly in some of the early intervention programs that are developing and elsewhere. But we really do need a much greater expansion of training and also just implementation, because it could be very valuable to a lot of people and it’s not really getting there yet.

Related Videos
Kimberly Westrich, MA, chief strategy officer at the National Pharmaceutical Council
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center
Jawad Haider Butt, MD, PhD
Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth
Barry Byrne, MD, PhD, Powell Gene Therapy Center at the University of Florida
JC Scott, CEO and president, PCMA
Caspian Oliai, MD, MS, a medical oncologist and hematologist and medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
Neha Kashalikar, PharmD, director of strategic pharmacy consulting, MassHealth
Adam Colburn, JD, vice president for congressional affairs, AMCP
Katrina Ortblad, ScD, MPH, Fred Hutch Cancer Center
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.